TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01793610

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparative-dose (40mg) MDMA
Description: An initial comparator-dose of 40 mg MDMA orally given at the start of two separate psychotherapy sessions scheduled 3 to 5 weeks apart, with the initial dose possibly followed 1.5 to 2.5 hours later by a supplemental dose half the size of the initial dose (20 mg MDMA).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active Dose 2 (100 mg) MDMA
Description: An initial dose of full-dose 100 mg MDMA orally given at the start of two separate psychotherapy sessions scheduled 3 to 5 weeks apart, with the initial dose possibly followed 1.5 to 2.5 hours later by a supplemental dose half the size of the initial dose (50 mg MDMA).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active Dose 1 (125 mg) MDMA
Description: An initial dose of full-dose 125 mg MDMA orally given at the start of two separate psychotherapy sessions scheduled 3 to 5 weeks apart, with the initial dose possibly followed 1.5 to 2.5 hours later by a supplemental dose half the size of the initial dose (62.5 mg MDMA).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Description: Psychotherapy conducted throughout experimental sessions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Description: Psychotherapy conducted throughout experimental sessions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychotherapy
Description: Psychotherapy conducted throughout experimental sessions.
Study: NCT03799601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: Anlotinib which has shown an affirmatory efficacy in ALTER0303 controlled trial as a 3rd-line treatment on advanced NSCLC is a tyrosine kinase inhibitor with a favorable safety profile in phase I trial which mainly targets VEGFR1/2/3, FGFR, PDGFR and c-kit.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: a chemotherapy medication used to treat a number of types of cancer.This includes breast cancer, head and neck cancer, stomach cancer, prostate cancer and non-small-cell lung cancer.It may be used by itself or along with other chemotherapy medication.It is given by slow injection into a vein.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin is used to treat a number of forms of cancer. This includes ovarian cancer, lung cancer, head and neck cancer, brain cancer, and neuroblastoma. It may be used for some types of testicular cancer but cisplatin is generally more effective.
Study: NCT01413399

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 4 degree chilled saline
Description: 4 degree chilled saline up to 2L in the prehospital setting

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 4 degree chilled saline
Description: 4 degree chilled saline up to 2L in the prehospital setting
Study: NCT00295854

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MN-001 BID
Description: Eligible patients received 500 mg MN-001 bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MN-001
Description: Eligible patients received 500 mg MN-001 once daily (qd)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Eligible patients received placebo
Study: NCT00290121

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Study: NCT03540810

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine
Description: The patients will additionally receive this drug with their usual treatment to evaluate its efficiency to prevent new thrombotic events in primary antiphospholipid syndrome patients

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The patients will receive placebo with their usual treatment
Study: NCT01400282

Intervention type: DEVICE
Group type: OTHER
Intervention: High frequency spinal cord stimulation

Intervention type: DEVICE
Group type: OTHER
Intervention: High frequency spinal cord stimulation
Study: NCT02958657

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Training
Description: Supervised exercise training program that includes two workouts per week for three months at a rehabilitation unit.
Study: NCT02577354

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ReActiv8 Implantable Stimulation System (Patient Appropriate Stimulation)
Description: ReActiv8 implanted and configured to deliver stimulation at a patient-appropriate level, and participants instructed to deliver stimulation in two 30-minute sessions per day.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ReActiv8 Implantable Stimulation System (Low Stimulation)
Description: ReActiv8 implanted and configured to deliver low stimulation, and participants instructed to deliver stimulation in two 30-minute sessions per day.
Study: NCT03756753

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Results available to provider
Description: Results of point of care testing are given to provider
Study: NCT04459663

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab injection combine with Axitinib
Description: The patients in the group will be infused intravenously with fixed dose of 240mg JS001 on the first day of each cycle. Oral Axitinib 5mg bid (recommended interval of about 12 hours) was given daily from the second day of the initial cycle
Study: NCT01711762

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0973
Description: Single oral dose of \[14C\]-GDC-0973
Study: NCT02097979

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Glaucoma Educational Intervention
Study: NCT03893721

Intervention type: DIAGNOSTIC_TEST
Intervention: arsenic exposure
Description: analysis of hair samples for Arsenic using Agilent graphite tube atomizer 120

Intervention type: DIAGNOSTIC_TEST
Intervention: arsenic exposure
Description: analysis of hair samples for Arsenic using Agilent graphite tube atomizer 120
Study: NCT01701986

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Bone Marrow Transplantation
Description: Undergo allogeneic BMT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo allogeneic BMT or PBSCT

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-Thymocyte Globulin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given IV then PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo allogeneic PBSCT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given IV then PO
Study: NCT03350334

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine
Description: Peri-operative Duloxetine administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo administration
Study: NCT00654719

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: NutriDrink
Description: Nutritional supplementation that contains 600 kcal/day: protein content 20 g, carbohydrates 72 g, fat 26 g

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Nutritional supplementation containing only 12 kcal/day
Study: NCT00533104

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: BM-MNC preparation
Description: For autologous bone marrow - mononuclear cells preparation, 500ml of bone marrow are collected under general anaesthesia; mononuclear cells are separated using a blood-cells separator (COBE SPECTRA, GAMBRO BCT) and concentrated to produce a final volume of 40ml.~Cells are implanted 1 to 3 hours after preparation by multiple intramuscular injections into the gastrocnemius of the ischemic leg.(30 injection sites, 1 to 1.5 cm deep, spaced 1 cm apart,1 ml per injection).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PB-MNC preparation
Description: Peripheral blood - mononuclear cells are collected through cytapheresis with the same blood-cells separator which is adjusted to obtain a 40 mL cell product. No previous mobilization with hematopoïetic growth-factor is administered.~Cells are implanted 1 to 3 hours after preparation by multiple intramuscular injections into the gastrocnemius of the ischemic leg.(30 injection sites, 1 to 1.5 cm deep, spaced 1 cm apart,1 ml per injection).
Study: NCT02837640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levodopa-carbidopa
Description: sinemet 200/50 1/2 tablet b.i.d. for 2 days and then t.i.d for 6 months
Study: NCT03255824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine and Midazolam
Description: Administration of Dexmedetomidine and Midazolam for sedation during third molar surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol, Midazolam, and Fentanyl
Description: Administration of Propofol, Midazolam, and Fentanyl for sedation during third molar surgery.
Study: NCT03924479

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PowerBreathe (Breathing muscle training)
Description: The breathing muscle breathing training will consist of using the PowerBreathe training for 8 weeks. The PowerBreathe is an inspiratory pressure threshold trainer.The valve blocks the airflow until the threshold pressure is achieved by breathing in forcefully into the device.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: PowerBreathe (Breathing muscle training)
Description: The breathing muscle breathing training will consist of using the PowerBreathe training for 8 weeks. The PowerBreathe is an inspiratory pressure threshold trainer.The valve blocks the airflow until the threshold pressure is achieved by breathing in forcefully into the device.
Study: NCT00198484

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitrase
Study: NCT00785291

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixabepilone
Description: Given IV
Study: NCT01125241

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: wuling capsule
Description: orally, three tablets each time,three times a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo of wuling capsule
Description: orally, three tablets each time and three times a day
Study: NCT04317573

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Personalised card
Description: An individualised card containing the patient's eye drops regime was printed for the patient after his/consult with the physician to be brought home.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Personalised card
Description: An individualised card containing the patient's eye drops regime was printed for the patient after his/consult with the physician to be brought home.
Study: NCT04180852

Intervention type: OTHER
Intervention: Functional tests without clinical consequence for the patients therapy
Description: Battery of tests, which measure the patients functional outcomes regarding their muscle mass, their muscle strength, fat mass, physical function, neuropsychological function and quality of life.

Intervention type: OTHER
Intervention: Functional tests without clinical consequence for the patients therapy
Description: Battery of tests, which measure the patients functional outcomes regarding their muscle mass, their muscle strength, fat mass, physical function, neuropsychological function and quality of life.

Intervention type: OTHER
Intervention: Functional tests without clinical consequence for the patients therapy
Description: Battery of tests, which measure the patients functional outcomes regarding their muscle mass, their muscle strength, fat mass, physical function, neuropsychological function and quality of life.

Intervention type: OTHER
Intervention: Functional tests without clinical consequence for the patients therapy
Description: Battery of tests, which measure the patients functional outcomes regarding their muscle mass, their muscle strength, fat mass, physical function, neuropsychological function and quality of life.

Intervention type: OTHER
Intervention: Functional tests without clinical consequence for the patients therapy
Description: Battery of tests, which measure the patients functional outcomes regarding their muscle mass, their muscle strength, fat mass, physical function, neuropsychological function and quality of life.
Study: NCT03424902

Intervention type: DIAGNOSTIC_TEST
Intervention: cardiac computed tomography and cardiac catheterization
Description: assesment of certain predictors with CT and fluroscopy for paravalvular leakage

Intervention type: DIAGNOSTIC_TEST
Intervention: cardiac computed tomography and cardiac catheterization
Description: assesment of certain predictors with CT and fluroscopy for paravalvular leakage
Study: NCT01909193

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention Bias Modification (ABM)
Description: Attention training via 8 weekly repeated trials of a dot-probe task intended to direct attention away from threat stimuli.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy
Description: CBT will consist of 16-20 weekly individual treatment sessions aimed to reduce symptoms via cognitive and behavioral interventions
Study: NCT03491046

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET scan
Description: low dose fluorodeoxyglucose (FDG) PET research scan with CEST sequence

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET scan
Description: low dose fluorodeoxyglucose (FDG) PET research scan with CEST sequence

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI scan
Description: standard of care MRI

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI scan
Description: standard of care MRI
Study: NCT01942486

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational Coating
Study: NCT03058250

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Transesophageal echocardiography
Study: NCT04167098

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PRP injection
Description: 0.5 ml Platelet-rich Plasma around A1 tendon sheath

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid injection
Description: 0.5 ml methylprednisolone around A1 tendon sheath

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo injection
Description: 0.5 ml 0.9% saline around A1 tendon sheath
Study: NCT01132248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mefloquine
Description: 15mg/kg mefloquine per dose Women receive two doses: One after the first trimester of pregnancy and the second at least one month after the first dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: S/P
Description: sulfadoxine-pyrimethamine IPTp will be administered following current WHO recommendations
Study: NCT02318355

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: normal saline
Description: Crystalloid intravenous solution

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: lactated ringers
Description: Crystalloid intravenous solution
Study: NCT01888445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: roxadustat
Description: oral
Study: NCT00785291

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Given IV

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT03139422

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid 500 MG
Description: oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium Dobesilate
Description: oral tablets
Study: NCT03313518

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS
Description: 15 patients received real anodal tDCS for 20 minutes daily for 10 consecutive days.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: 15 patients received sham anodal tDCS for 20 minutes daily for 10 consecutive days.
Study: NCT04960605

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Dental implants
Description: Treatment of the toothless regions with dental implants

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Dental implants
Description: Treatment of the toothless regions with dental implants
Study: NCT02987075

Intervention type: OTHER
Group type: OTHER
Intervention: Compacting embryo transferring
Description: transfer of 2 utilizable compacting embryos

Intervention type: OTHER
Group type: OTHER
Intervention: Non- compacting embryo transferring
Description: transfer of 2 utilizable non-compacting embryos have 7-9 cells with under 20% fragmentation.
Study: NCT05519280

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: the Biopsychosocial-Spiritual Group Intervention
Description: The Experimental group received 8 sessions of weekly BPS-S group therapy for 80 minutes each.
Study: NCT02057874

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3 Tesla Magnetic Resonance Imaging
Description: 3T MRI consists of a series of radiofrequency (RF) pulse sequences optimized for acquiring CEST-, MT-, DW-, and DCE-MRI data in one seamless imaging examination. For DCE, MR contrast agent will be intravenously administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnevist® (Intravenous (IV) administration of MRI contrast agent)
Description: For the acquisition of DCE-MR data, the FDA-approved contrast agent Magnevist® (gadopentetate dimeglumine, 0.1 mmol/kg) will be delivered intravenously by the MR technologist at a rate of 2 mL/sec (followed by a saline flush) via a power injector after the acquisition of a set of baseline dynamic scans. The entire sequence lasts approximately 8 minutes.
Study: NCT01866943

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: Tranexamic Acid 1.5 g (100 mg/mL)in 100cc normal saline is applied topically to the wound for 5 minutes time then suctioned and the skin closed. The control group receives just normal saline and no drug.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline Solution
Study: NCT01568099

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AFFITOPE® PD01A
Description: s.c. injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AFFITOPE® PD01A
Description: s.c. injection

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Untreated control
Study: NCT02520167

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary and Lifestyle Counseling
Description: Dietary and lifestyle education; Peer group support.
Study: NCT00752843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mifepristone + fluvastatin
Description: Subjects will receive a single oral dose of 40 mg PO of fluvastatin on three occasions: alone (Day 1), at the same time as a single dose of CORLUX 1200 mg (Day 8) and during concomitant administration of CORLUX 1200 mg/day (CORLUX on Days 8-14, fluvastatin on Day 14).
Study: NCT02943850

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stem cell (HPC) implantation
Description: All patients will received unilateral lumbar spinal cord injections of CNS10-NPC-GDNF cells.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stereotactic surgical device
Description: A newly developed stereotactic frame is being evaluated as a part of this trial
Study: NCT02037048

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxaliplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: leucovorin calcium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluorouracil
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo therapeutic conventional surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: therapeutic conventional surgery
Description: Undergo therapeutic conventional surgery

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo radiation therapy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy
Description: Undergo radiation therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV
Study: NCT00892502

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bismuth tablets
Description: 1000 mg x 2 for five days prior to chemotherapy/radiotherapy 500 mg x 2 for ten days during and after chemotherapy/radiotherapy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablets
Description: 1000 mg x 2 for five days prior to chemotherapy/radiotherapy 500 mg x 2 for ten days during and after chemotherapy/radiotherapy
Study: NCT01410058

Intervention type: DIETARY_SUPPLEMENT
Intervention: Moringa oleifera
Description: leaf powder, 1.85g once daily, hard gelatin capsules

Intervention type: DIETARY_SUPPLEMENT
Intervention: Moringa oleifera
Description: leaf powder, 1.85g once daily, hard gelatin capsules

Intervention type: DRUG
Intervention: Efavirenz 600mg
Description: Efavirenz 600mg based regimen

Intervention type: DRUG
Intervention: Nevirapine 200Mg Oral Tablet
Description: Nevirapine 200mg based regimen